irritable bowel syndrome (IBS) - Articles and news items

RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial

Industry news / 26 April 2017 / Niamh Marriott, Junior Editor

RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda for the treatment of diarrhoea-predominant irritable bowel syndrome…

First patients dosed in Bekinda IBS-D trial

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+